NCT06211647 - A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

Advanced Solid Tumor

Interventions

DRUG

[177Lu]Lu-XT117

\[177Lu\]Lu-XT117 is a radiopharmaceutical therapy in which an beta emitter, Lu-177, is conjugated to XT117. Patients will receive \[177Lu\]Lu-XT117 administration at fixed dose levels at an interval of 6 weeks between each dose.

Trial Locations (1)

Unknown

RECRUITING

The First Medical Center, Chinese PLA General Hospital, Beijing

All Listed Sponsors

collaborator

Sinotau Pharmaceutical Group

INDUSTRY

lead

Ruimin Wang

OTHER